Literature DB >> 12091083

Detection of herpesvirus genomes by polymerase chain reaction in cerebrospinal fluid and clinical findings.

Sophie Minjolle1, C Arvieux, A L Gautier, I Jusselin, R Thomas, C Michelet, Ronald Colimon.   

Abstract

BACKGROUND: The viruses of the Herpesviridae family, in particular herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), and human herpesvirus 6 (HHV-6), are responsible for numerous infections of the central nervous system (CNS). These infections manifest as diverse clinical signs, many of which are not specific. The diagnosis of these infections is necessary to make it possible to adapt treatment appropriately, as treatment is specific for the particular virus concerned.
OBJECTIVES: To apply a polymerase chain reaction (PCR) technique for the diagnosis in a single reaction of the six herpesviruses most frequently detected in the cerebrospinal fluid (CSF) and to analyse clinical events in patients presenting positive results in PCR for herpesviruses. STUDY
DESIGN: We studied 141 patients, from whom 180 CSF samples were collected. The clinical files of the patients were consulted retrospectively, and a list of clinical signs was recorded. After testing by targeted PCR, at the clinician's demand, we tested these samples by herpes consensus PCR, which detects six herpesviruses (HSV-1, HSV-2, CMV, EBV, VZV, HHV-6), in a single PCR.
RESULTS: Targeted PCR tests identified 25 CSF samples (13.9%), corresponding to 18 patients (12%), as positive. The herpes consensus PCR test detected 49 samples (27.2%) as positive, resulting in the identification of 54 individual viruses (four samples displayed co-infection) from 39 patients (27%). 130 CSF samples, from 101 patients, tested negative by both techniques. 23 HIV-positive patients (30.6%), three HIV-negative immunocompromised patients (27%), and 14 immunocompetent patients (25%) were CSF PCR-positive. In HIV-positive patients, CMV was the virus most frequently identified (13%), followed by EBV (10.6%), VZV (5.3%) and finally HSV-1 and HSV-2 (both 1.3%). We did not detect HHV-6 in any of these samples. We detected only HSV-2, EBV and VZV in the 11 HIV-negative immunocompromised patients. CSF samples of immunocompetent patients contained mostly VZV (9%) and HSV-1 (7.3%).
CONCLUSIONS: The herpes consensus PCR for a given virus was more sensitive than the standard, targeted PCR used in our laboratory. The clinical signs presented by patients infected with HSV-1, HSV-2 and CMV were similar to those reported in previous studies. For VZV, we report the possibility of mild, transient cerebral viral reactivation. Our data on the detection of EBV by PCR suggest that the PCR test is of predictive value for cerebral lymphoma in immunocompromised patients. The possible role of HHV-6 in a subacute neurological disorder merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091083     DOI: 10.1016/s1386-6532(02)00035-5

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  10 in total

Review 1.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Factors influencing PCR detection of viruses in cerebrospinal fluid of patients with suspected CNS infections.

Authors:  N W S Davies; L J Brown; J Gonde; D Irish; R O Robinson; A V Swan; J Banatvala; R S Howard; M K Sharief; P Muir
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

3.  Patients with an acute zonal occult outer retinopathy-like illness rapidly improve with valacyclovir treatment.

Authors:  Vinit B Mahajan; Edwin M Stone
Journal:  Am J Ophthalmol       Date:  2010-08-05       Impact factor: 5.258

4.  The effect of highly active antiretroviral therapy on outcome of central nervous system herpesviruses infection in Cuban human immunodeficiency virus-infected individuals.

Authors:  Pedro Ariel Martínez; René Díaz; Daniel González; Lisset Oropesa; Ruby González; Lissette Pérez; Jenniffer Viera; Vivian Kourí
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

5.  Varicella zoster virus infection in neurological patients in Bulgaria.

Authors:  Evelina Shikova; Antoniya Kumanova; Ivailo Tournev; Sashka Zhelyazkova; Evgenia Vassileva; Ivan Ivanov; Maria Pishmisheva
Journal:  J Neurovirol       Date:  2021-03-04       Impact factor: 2.643

6.  Unusual MRI findings in an immunocompetent patient with EBV encephalitis: a case report.

Authors:  Paola Di Carlo; Marcello Trizzino; Lucina Titone; Giuseppina Capra; Piero Colletti; Giovanni Mazzola; Daniela Pistoia; Caterina Sarno
Journal:  BMC Med Imaging       Date:  2011-03-24       Impact factor: 1.930

7.  Designing novel and simple competitive internal amplification control for reliable PCR diagnosis of herpes simplex virus.

Authors:  Asiye Akbarian; Mohammad Hassan Shahhosseiny; Somayeh Vafaei; Elham Moslemi; Maryam Ghahri
Journal:  Jundishapur J Microbiol       Date:  2015-02-20       Impact factor: 0.747

8.  Application of molecular diagnostic techniques for viral testing.

Authors:  Fernando Cobo
Journal:  Open Virol J       Date:  2012-11-30

9.  Usefulness of Herpes Consensus PCR methodology to routine diagnostic testing for herpesviruses infections in clinical specimens.

Authors:  Georgia Vrioni; Christos Kalogeropoulos; Constantina Gartzonika; Efthalia Priavali; Stamatina Levidiotou
Journal:  Virol J       Date:  2007-06-12       Impact factor: 4.099

10.  Comparison of nested PCR and real time PCR of Herpesvirus infections of central nervous system in HIV patients.

Authors:  Lorenzo Drago; Alessandra Lombardi; Elena De Vecchi; Giuseppe Giuliani; Rosaria Bartolone; Maria Rita Gismondo
Journal:  BMC Infect Dis       Date:  2004-11-30       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.